Scinai Immunotherapeutics Reports Impressive Q1 Revenue Surge
Scinai Immunotherapeutics Reports Financial Achievements Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in innovative treatments for inflammation and immunology (I&I) diseases, recently shared its remarkable financial results for Q1 2025. This report highlights significant progress in its Contract Development and Manufacturing...
Continue Reading